Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CASI PharmaceuticalsCASIF +1.40%29 3-Year EPS without NRI Growth Rate is -5.40% as of Dec. 2025. GuruFocus rates CASIF with a GF Score™ of 29/100 and a GF Value™ of $1.10 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 1,160 Biotechnology companies, CASI Pharmaceuticals ranks worse than 76.29% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was -5.40% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 2.90% per year.
During the past 10 years, the average EPS without NRI Growth Rate was -1.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of CASI Pharmaceuticals was 48.50% per year. The lowest was -67.00% per year. And the median was 11.10% per year.
CASI Pharmaceuticals (OTCPK:CASIF) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
CASI Pharmaceuticals 3-Year EPS without NRI Growth Rate Related Terms
CASIF vs DCOY, PKTX, BIXT: 3-Year EPS without NRI Growth Rate Comparison
For the Biotechnology subindustry, CASI Pharmaceuticals's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CASI Pharmaceuticals 3-Year EPS without NRI Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CASI Pharmaceuticals's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where CASI Pharmaceuticals's 3-Year EPS without NRI Growth Rate falls into.
CASI Pharmaceuticals 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of -5.40% mean?
CASI Pharmaceuticals (CASIF) has a 3-Year EPS without NRI Growth Rate of -5.40% as of Dec. 2025. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for CASI Pharmaceuticals and its competitors. According to the industry distribution chart, CASI Pharmaceuticals ranks #885 out of 1160 companies in the Biotechnology industry, placing it in the top 76.3%.
Is CASI Pharmaceuticals' 3-Year EPS without NRI Growth Rate too high?
CASI Pharmaceuticals' current 3-Year EPS without NRI Growth Rate is -5.40%. Based on the distribution chart, CASI Pharmaceuticals ranks #885 out of 1160 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, CASI Pharmaceuticals has a GF Score™ of 29/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does CASI Pharmaceuticals' 3-Year EPS without NRI Growth Rate compare to DCOY and PKTX?
According to the Biotechnology industry distribution chart, CASI Pharmaceuticals ranks #885 out of 1160 companies for 3-Year EPS without NRI Growth Rate. This places CASI Pharmaceuticals in the lower half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 16.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Biotechnology company?
The median 3-Year EPS without NRI Growth Rate among Biotechnology companies is 16.20, based on 1,160 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for CASI Pharmaceuticals and its competitors. For the Biotechnology industry, the median 3-Year EPS without NRI Growth Rate is 16.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CASI Pharmaceuticals's current 3-Year EPS without NRI Growth Rate is -5.40%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CASI Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, CASI Pharmaceuticals (CASIF) is currently considered Possible Value Trap. The stock's GF Value™ is $1.10, compared to a current price of $0.15 — trading 86.5% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is -5.40%. CASI Pharmaceuticals' overall GF Score™ is 29/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For CASI Pharmaceuticals (CASIF), the current 3-Year EPS without NRI Growth Rate is -5.40% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CASI Pharmaceuticals (CASIF) Overvalued in 2026?
Based on GuruFocus' analysis, CASI Pharmaceuticals stock appears to be undervalued.
The current stock price of $0.15 is trading 86.5% below its estimated GF Value™ of $1.10.
GuruFocus considers CASI Pharmaceuticals to be Possible Value Trap.
Key valuation signals for CASIF:
3-Year EPS without NRI Growth Rate: -5.40%
GF Value™: $1.10 vs. price of $0.15 (86.5% below fair value)
No single metric tells the full story. See the CASIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CASI Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing CID-103, an anti-CD38 monoclonal antibody, for patients with organ transplant rejection and autoimmune diseases. Additionally, the company manages its other assets, including EVOMELA, FOLOTYN, CNCT19, BI-1206, and CB-5339, with a primary strategic emphasis on advancing CID-103 toward key clinical and regulatory milestones. It also distributes YuTuo (Zimberelimab), a fully human anti-PD-1 monoclonal antibody for patients with relapsed or refractory classical Hodgkin's lymphoma and recurrent or metastatic cervical cancer. Geographically, the company's revenue is solely generated in Mainland China.
29GF Score
Get the complete analysis for CASIF
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CASIF has been successfully added to your 
